The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Randomized Phase III Study Comparing Conventional-Dose Doxorubicin Plus Ifosfamide Versus High-Dose Doxorubicin Plus Ifosfamide Plus Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Soft Tissue Sarcomas: A Trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group
Abstract
PURPOSE: This randomized multicenter study was designed to compare the activity of a high-dose doxorubicin-containing chemotherapy regimen with a conventional standard-dose regimen in adult patients with advanced soft tissue sarcomas (ASTS). PATIENTS AND METHODS: Between 1992 and 1995, 314 patients were randomized to receive a standard-dose regimen (arm A), containing doxorubicin (50 mg/m 2 on day 1) and ifosfamide (5 g/m 2 on day 1), or an intensified regimen (arm B), combining doxorubicin (75 mg/m 2 on day 1), the same ifosfamide dose, and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF; sargramostim, 250 μg/m 2 on days 3 to 16); all courses were repeated every 3 weeks. RESULTS: The median age of the 294 eligible patients was 50 years. They received a median of five chemotherapy cycles. The median dose and relative doxorubicin dose-intensity achieved were 245 mg and 97% in arm A and 360 mg and 99% in arm B, respectively. Thirty-eight percent and 23% of patients presented with leiomyosarcomas and liver metastases, respectively. Objective responses were observed in 31 (21%) of 147 assessable patients in arm A and in 31 (23.3%) of 133 in arm B (P = .65). No change was observed in 41.6% and 46.2% of patients in arm A and B, respectively. Progression-free survival (PFS) was significantly longer in the intensive arm (P = .03). The median duration of the time to progression was 19 weeks in the conventional arm and 29 weeks in the intensified arm. There was no difference in overall survival (P = .98) between the two therapeutic arms. Toxicities were manageable in both arms. A grade 3/4 neutropenia and infection occurred in 92% and 4.6% of patients in arm A, respectively, and in 90% and 16.6% in arm B, respectively. Grade 3/4 thrombocytopenia was more frequent in arm B. CONCLUSION: The use of rhGM-CSF allowed safe escalation of chemotherapy doses. Despite a 50% increase of the doxorubicin dose-intensity, the high-dose regimen failed to demonstrate any impact on survival in patients with ASTS. The low complete response rate, the high incidence of leiomyosarcomas, and liver metastases may in part explain these results. However, the lengthening of the PFS in the intensive arm, because of the quality of stable disease and inappropriate tumor evaluation policies that potentially lead to an underestimation of antitumor activity, does not definitively refute the use of a high-dose chemotherapy regimen in selected patients with ASTS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486
Long-term results of lung metastasectomy: Prognostic analyses based on 5206 cases
Pastorino, U., Buyse, M., Friedel, G., Ginsberg, R. J., Girard, P., Goldstraw, P., Johnston, M., McCormack, P., Pass, H., & Putnam, J. B. (1997) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(97)70397-0 · Cited by 1,529
Van Glabbeke, M., van Oosterom, A. T., Oosterhuis, J. W., Mouridsen, H., Crowther, D., Somers, R., Verweij, J., Santoro, A., Buesa, J., & Tursz, T. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.150 · Cited by 608
Self-citationSantoro, A., Tursz, T., Mouridsen, H., Verweij, J., Steward, W., Somers, R., Buesa, J., Casali, P., Spooner, D., & Rankin, E. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1537 · Cited by 526
Self-citationEdmonson, J. H., Ryan, L. M., Blum, R. H., Brooks, J. S., Shiraki, M., Frytak, S., & Parkinson, D. R. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.7.1269 · Cited by 516
Antman, K. H., Crowley, J. J., Balcerzak, S. P., Rivkin, S. E., Weiss, G. R., ELIAS, A. D., Natale, R. B., Cooper, R. M., Barlogie, B., & Trump, D. L. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.7.1276 · Cited by 478
Dose response evaluation of adriamycin in human neoplasia
O'Bryan, R. M., Baker, L. H., Gottlieb, J. E., Rivkin, S. E., Balcerzak, S. P., Grumet, G. N., Salmon, S. E., Moon, T. E., & Hoogstraten, B. (1977) · Cancer · doi:10.1002/1097-0142(197705)39:5<1940::aid-cncr2820390505>3.0.co;2-0 · Cited by 385
Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas.
Borden, E. C., Amato, D. A., Rosenbaum, C., Enterline, H. T., Shiraki, M. J., Creech, R. H., Lerner, H. J., & Carbone, P. P. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.6.840 · Cited by 299
Bramwell, V. H. C., Mouridsen, H. T., Santoro, A., Blackledge, G., Somers, R., Verwey, J., Dombernowsky, P., Onsrud, M., Thomas, D., Sylvester, R., et al. (1987) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(87)90075-7 · Cited by 243
Self-citationLe Cesne, A., Antoine, E., Spielmann, M., Le Chevalier, T., Brain, E., Toussaint, C., Janin, N., Kayitalire, L., Fontaine, F., & Genin, J. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1600 · Cited by 207
Self-citation
Cited by
Demetri, G. D., von Mehren, M., Jones, R. L., Hensley, M. L., Schuetze, S. M., Staddon, A., Milhem, M., Elias, A., Ganjoo, K., Tawbi, H., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.4734 · Cited by 841
Clinical management of gastrointestinal stromal tumors: Before and after STI-571
Dematteo, R. P., Heinrich, M. C., El-Rifai, W. M., & Demetri, G. (2002) · Human Pathology · doi:10.1053/hupa.2002.124122 · Cited by 637
Tap, W. D., Jones, R. L., Van Tine, B. A., Chmielowski, B., Elias, A. D., Adkins, D., Agulnik, M., Cooney, M. M., Livingston, M. B., Pennock, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30587-6 · Cited by 584
Woll, P. J., Reichardt, P., Le Cesne, A., Bonvalot, S., Azzarelli, A., Hoekstra, H. J., Leahy, M., Van Coevorden, F., Verweij, J., Hogendoorn, P. C., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70346-7 · Cited by 583
Self-citationDemetri, G. D., Chawla, S. P., von Mehren, M., Ritch, P., Baker, L. H., Blay, J. Y., Hande, K. R., Keohan, M. L., Samuels, B. L., Schuetze, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.0088 · Cited by 538
Self-citation
Metadata
- Authors
- Le Cesne, A., Judson, I., Crowther, D., Rodenhuis, S., Keizer, H. J., Van Hoesel, Q., Blay, J. Y., Frisch, J., Van Glabbeke, M., Hermans, C., Van Oosterom, A., Tursz, T., & Verweij, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-07-14
- Volume
- 18
- Issue
- 14
- Pages
- 2676-2684
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1828438395
- Cited by
- 256
- References
- 21
- FWCI
- 9.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized Phase III Study Comparing Conventional-Dose Doxorubicin Plus Ifosfamide Versus High-Dose Doxorubicin Plus Ifosfamide Plus Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Soft Tissue Sarcomas: A Trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. https://app.cochat.ai/papers/10.1200/jco.2000.18.14.2676
- The paper
- Le Cesne, A., Judson, I., Crowther, D., Rodenhuis, S., Keizer, H. J., Van Hoesel, Q., Blay, J. Y., Frisch, J., Van Glabbeke, M., Hermans, C., Van Oosterom, A., Tursz, T., & Verweij, J. (2000). Randomized Phase III Study Comparing Conventional-Dose Doxorubicin Plus Ifosfamide Versus High-Dose Doxorubicin Plus Ifosfamide Plus Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Soft Tissue Sarcomas: A Trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2000.18.14.2676
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.